帕利哌酮与奥氮平治疗首发精神分裂症患者的疗效观察

中国临床药理学与治疗学 ›› 2017, Vol. 22 ›› Issue (4): 466-470.

帕利哌酮与奥氮平治疗首发精神分裂症患者的疗效观察

崔力军，潘鑫，朱洁琳，李建华

湖州市第三人民医院精神科，湖州 313000，浙江

收稿日期:2016-12-27 修回日期:2017-03-27 出版日期:2017-04-26 发布日期:2017-04-26
通讯作者: 李建华，男，硕士，副主任医师，研究方向：精神分裂症的基础与临床。 Tel：13706531743 E-mail:lichienhua@sina.com
作者简介:崔力军，男，硕士，主治医师，研究方向：精神分裂症的基础与临床。 Tel：18767229824 E-mail:cuilijun0704@126.com
基金资助:
湖州市科技局项目（2014GYB31）

Effect of paliperidone and olanzapine on patients with first-episode schizophrenia

CUI Lijun, PAN Xin, ZHU Jielin, LI Jianhua

the Third People's Hospital of Huzhou, Psychiatric Department, Huzhou 313000, Zhejiang, China

Received:2016-12-27 Revised:2017-03-27 Online:2017-04-26 Published:2017-04-26

摘要/Abstract

摘要：

目的: 探讨帕利哌酮与奥氮平治疗首发精神分裂症患者的疗效及对糖代谢、血清脑源性神经营养因子（brain-derived neurotrophic factor，BDNF）浓度的影响。方法: 80例首发精神分裂症患者随机分为帕利哌酮组40例和奥氮平组40例，治疗8周。用阳性和阴性症状量表（positive and negative syndrome scale，PANSS）评定临床疗效，用副反应量表（treatment emergent symptom scale, TESS）评估不良反应。于基线期以及第4和8周末检测两组的空腹血糖（fasting blood sugar, FBS），用酶联免疫吸附法（enzyme-linked immuno sorbent assay, ELISA）检测血清BDNF浓度。结果: ①治疗8周后，帕利哌酮组总有效率68.4%，与奥氮平组的63.1%相似（P>0.05）；②两组在治疗4周、8周末的PANSS总分及各因子分均较基线期有明显降低（P<0.05），组间阳性和阴性症状评分差异无统计学意义（P>0.05）；③组内相比，奥氮平组8周末FBS水平较4周末明显升高，差异有统计学意义（P<0.01），而帕利哌酮组差异无统计学意义（P>0.05）；组间比较，8周末奥氮平组FBS水平较帕利哌酮组明显升高, 差异有统计学意义（P<0.01）；④与基线期相比，治疗4、8周末两组BDNF浓度均有明显升高（P<0.01），组间比较，8周末帕利哌酮组BDNF浓度较奥氮平组明显升高，有统计学意义（P<0.01）。结论: 帕利哌酮治疗精神分裂症的疗效与奥氮平相当，对糖代谢影响及升高血清BDNF的浓度优于奥氮平。

关键词: 精神分裂症, 帕利哌酮, 奥氮平, 糖代谢, 脑源性神经营养因子

Abstract:

AIM: To explore the effect of paliperidone and olanzapine treating patients with first-episode schizophrenia and their influence on sugar metabolism and serum levels of brain-derived neurotrophic factor (BDNF). METHODS: 80 patients with first-episode schizophrenia were randomly divided into paliperidone group (n=40) and olanzapine group (n=40) for an 8-week study. Positive and Negative Syndrome Scale (PANSS) was used to assess clinical efficacy, at the same time the Treatment Emergent Symptom Scale (TESS) was used to assess treatment of adverse reactions. Fasting blood sugar of the two groups at baseline, 4th and 8th weekend were detected, and serum levels of BDNF were measured by enzyme-linked immuno sorbent assay (ELISA). RESULTS:The effective rate was similar (68.4% vs.63.1%, P>0.05 ) after 8 weeks of treatment; In both groups, the factors and total scores of PANSS at the 4th, 8th weekend were significantly lower than those at the baseline, the difference was statistically significant (P<0.05), yet positive and negative symptoms score had no statistical significant differences between two groups. Comparison between the groups, olanzapine group FBS levels at 8th weekend had increased significantly than the 4th weekend (P<0.01), and paliperidone group had no significant differences. Comparison between groups, FBS levels in olanzapine group were obviously higher than those of paliperidone groups at the 8th weekend, the difference was statistically significant (P<0.01). BDNF concentrations of two groups were significantly higher at 4th, 8th weekend than those at the baseline (P<0.01). Comparison between groups, BDNF concentration in paliperidone group was obviously higher than that of olanzapine groups at the 8th weekend, the difference was statistically significant (P<0.01). CONCLUSION: Paliperidone and olanzapine have similar clinical efficacy in treating first-episode schizophrenia, paliperidone is better than olanzapine in regulating sugar metabolism index and elevated serum concentration of BDNF.

Key words: schizophrenia, paliperidone, olanzapine, sugar metabolism, brain-derived neurotrophic factor

中图分类号:

R794.3

崔力军，潘鑫，朱洁琳，李建华. 帕利哌酮与奥氮平治疗首发精神分裂症患者的疗效观察[J]. 中国临床药理学与治疗学, 2017, 22(4): 466-470.

CUI Lijun, PAN Xin, ZHU Jielin, LI Jianhua. Effect of paliperidone and olanzapine on patients with first-episode schizophrenia[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(4): 466-470.

参考文献

［1］李彪, 迟正锁, 陈贝, 等. 氨磺必利、帕利哌酮缓释片、奥氮平对首发未用药精神分裂症患者认知、记忆功能的影响［J］. 国际精神病学杂志, 2015 , 42(5): 14-17.
［2］Uehara T, Sumiyoshi T, Kurachi M. New pharmacotherapy targeting cognitive dysfunction of schizophrenia via modulation of gaba neuronal function［J］. Curr Neuro Pharmacol, 2015, 13(6): 793-801.
［3］吕建宝，邸晓兰，牛雅娟，等. 帕利哌酮缓释片对精神分裂症急性期体质量和血糖血脂的影响［J］. 中国新药杂志, 2013, 22(23): 2405-2409.
［4］吴庆锋, 蒋健昌, 苏珊娜, 等. 帕利哌酮与奥氮平对首发精神分裂症患者血浆瘦素和胰岛素水平的影响［J］. 中国医药指南, 2014, 12(18): 7-9.
［5］Ajami A, Hosseini SH, Taghipour M, et al. Changes in serum levels of brain derived neurotrophic factor and nerve growth factor-beta in chizophrenic patients before and after treatment ［J］. Scand J Immunol, 2014, 80(1): 36-42.
［6］Goto N, Yoshimura R, Kakeda S, et al. Comparison of brain N-acetylaspartate levels and serum brain-derived neurotrophic factor (BDNF) levels between patients with first-episode schizophrenia psychosis and healthy controls［J］. Eur Psychiatry, 2011, 26(1): 57-63.
［7］牛莉莉, 温科奇, 熊鹏, 等. 首发精神分裂症治疗前后血清NGF、BDNF、GFAP 与临床症状的相关性研究［J］. 精神医学杂志, 2015, 28(1): 10-12.
［8］何燕玲, 张明园. 阳性和阴性综合症量表及其应用［J］. 临床精神医学杂志, 1997, 7(6): 353.
［9］张鸿燕, 李华芳, 王刚, 等. 帕利哌酮缓释片治疗急性精神分裂症疗效及安全性的对照研究［J］. 中华精神科杂志，2011, 24(6): 441-443.
［10］Smith G, Vickers M, Shepherd P. Olanzapine effects on body composition,food preference,glucose metabolism and insulin sensitivity in the rat ［J］. Arch Physiol Biochem, 2011,117(4): 241-249.
［11］Haupt DW. Differential metabolic effects of antipsychotic treatments ［J］. Eur Neuro Psycho Pharmaco, 2006, 16(3):149-155.
［12］韩海洋, 彭淑芹, 徐向东. 逍遥散对抑郁模型大鼠海马中枢神经递质含量及BDNF和TrkB表达的影响［J］. 长春中医药大学学报, 2015, 31(5): 893-896.
［13］Autry A, Monteggia L. Brain-derived neurotrophic factor and neuropsychiatric disorders［J］. Pharmacol Rev, 2012, 4(2): 238-258.
［14］Ajami A, Hosseini S, Taghipour M, et al. Changes in serum levels of brain derived neurotrophic factor and nerve growth factor-beta in schizophrenic patients before and after treatment［J］. Scand J Immunol, 2014, 80(1): 36-42.
［15］Stranahan A, Arumugam T, Mattson M. Lowering crticosterone levels reinstates hippocampal Brian-Derivde Neurotropic Facror and Trk B expression without influencing deficits in hypothalamic Brian-Derivde Neurotropic Facror expression in leptin receprot-deficient mice［J］. Neuroendocrinology, 2011, 93(1): 58-64.

[1]	李豪, 李玲, 夏志平, 叶啟发, 彭贵主. FXR激动剂GW4064改善他克莫司诱导的移植术后糖尿病[J]. 中国临床药理学与治疗学, 2022, 27(4): 466-472.
[2]	魏继芳, 岳红梅, 刘南玉, 宋佩佩, 谢莹莹, 王嘉琪, 魏雅倩. 甲状腺激素与特发性肺纤维化相关性的研究进展[J]. 中国临床药理学与治疗学, 2022, 27(3): 307-313.
[3]	杨贺淳, 史道华 . 调控肿瘤糖代谢重编程改善肿瘤耐药的小分子抑制剂研究进展[J]. 中国临床药理学与治疗学, 2021, 26(7): 836-840.
[4]	李娜, 韩鸿璨, 王骏. 以药动学方法评价的抗精神分裂症药物人体生物等效性研究的一般考虑[J]. 中国临床药理学与治疗学, 2021, 26(12): 1419-1425.
[5]	闫盼, 施剑飞, 李静, 王晟东, 王姝琪, 汪程鹏, 宋明芬. DRD2和5-HTR2A基因多态性及其交互作用对奥氮平治疗精神分裂症疗效的影响[J]. 中国临床药理学与治疗学, 2020, 25(10): 1131-1138.
[6]	万萍，刘亮，张萍，张忠东. 奥氮平在精神分裂症中的血清药物浓度/剂量比影响因素研究[J]. 中国临床药理学与治疗学, 2019, 24(9): 1024-1029.
[7]	周严灿. 阿戈美拉汀治疗抑郁障碍的疗效及对脑源性神经营养因子的影响[J]. 中国临床药理学与治疗学, 2019, 24(6): 699-703.
[8]	胡德凤，王轶虎，龙小宇，王广水. 甘麦大枣汤加减方联合认知行为干预对精神分裂症超高危人群的干预作用及对认知功能、生活质量及血清5-HT、MT、TSH水平的影响[J]. 中国临床药理学与治疗学, 2019, 24(5): 546-553.
[9]	樊垚，薛永，汪昕，陈雪菲，张旭，姚应水，沈冲. 载脂蛋白E基因多态性与利培酮所致体质量降低的关联研究[J]. 中国临床药理学与治疗学, 2019, 24(3): 288-295.
[10]	官俏兵，韩晨阳，储志远，杨毅，张晓玲. 丁苯酞通过激动cAMP/CREB/BDNF信号通路改善小鼠缺血再灌注后认知障碍的作用机制[J]. 中国临床药理学与治疗学, 2019, 24(2): 152-157.
[11]	曹婷，李娜娜，蔡骅琳. 神经甾体在精神分裂症发病与治疗中作用的研究进展[J]. 中国临床药理学与治疗学, 2018, 23(6): 709-714.
[12]	章晓英，王康，邬莎，郭鹏. 低剂量奥氮平控制抗NMDAR脑炎精神症状的联系分析[J]. 中国临床药理学与治疗学, 2018, 23(11): 1292-1296.
[13]	杨琴，杜青，赵洪庆，王宇红，韩远山，杨蕙，孟盼 . 百合疏肝安神汤对焦虑性抑郁症模型大鼠前额叶-边缘结构及GR/BDNF/NPY表达的影响[J]. 中国临床药理学与治疗学, 2017, 22(10): 1090-1098.
[14]	周勇，陈雪芳，黄汉津. 氨磺必利治疗精神分裂症疗效以及安全性研究[J]. 中国临床药理学与治疗学, 2017, 22(10): 1152-1157.
[15]	李霞，肖笛，寇皓，张郦，纪振宇，郭喻，汪晖. 孕期乙醇暴露所致高脂饮食子代大鼠糖代谢功能改变[J]. 中国临床药理学与治疗学, 2017, 22(1): 20-26.